We studied 90 adults undergoing surgical removal of at least both lower third molar teeth as day cases under standardized general anaesthesia. Patients were allocated randomly (with stratification for surgeon) to receive tenoxicam 40 mg, tenoxicam 20 mg or placebo i.v. at induction of anaesthesia and orally (effervescent tablets) with food on each of the subsequent 2 days. Panadeine (paracetamol 500 mg-codeine 8 mg) was given before operation and was available as needed for pain thereafter, to a limit of two tablets every 4 h. Nefopam i.v. was also available. Efficacy variables and adverse reactions were assessed over 6 days. Over the 6-day period, patients who received tenoxicam reported less pain on rest (area under the curve; P:0.05) and less disturbance in sleep (P:0.01) even though they used fewer Panadeine tablets (P:0.05). Differences between tenoxicam 40 mg and 20 mg were not significant. There was no significant difference in nefopam requirements or side effects, and no adverse event attributable to the study medication. (Br.
Pain may last for several days after oral surgery; it is often managed with paracetamol or paracetamolcodeine combinations. Recently, it has become popular for such regimens to be supplemented with non-steroidal anti-inflammatory drugs (NSAID), [1] [2] [3] and tenoxicam is well suited for this because it can be administered once a day parenterally or enterally as it has a long half-life (60-70 h). 4 Ketorolac is also suitable for parenteral and enteral administration but it has a short half-life of 4-6 h and needs to be given four times a day. 5 Diclofenac can be used parentally but i.m. administration is associated with muscle damage 6 and i.v. administration causes thrombophlebitis unless the drug is well diluted. 7 The analgesic efficacy of tenoxicam has been well documented in comparison with placebo in chronic pain and inflammation 4 8 and in several controlled studies in the perioperative setting. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Those comparing tenoxicam with placebo, saline or no specific treatment have shown no benefit 26 or some combination of reduced consumption of opioids 9 10 12 14 15 or other analgesics, 11 lower pain scores, 10 13 better pain relief and a longer time to request for first analgesia. 10 11 There may be benefit in intra-articular injection, 22 24 or in mixing tenoxicam with local anaesthetic in regional i.v. analgesia, 21 27 but not in local infiltration of the drug. 20 23 Comparisons with other NSAID have shown somewhat similar efficacy, 17 19 although onset of analgesia seems to be slower than with diclofenac. 19 25 No advantage was demonstrated with tenoxicam 40 mg orally compared with paracetamol 1000 mg orally immediately before oral surgery, 16 and the possibility of benefit from combining paracetamol (with or without codeine) and tenoxicam has not been investigated. Given the side effects of NSAID and the relative safety of paracetamol (with and without codeine), 1 we thought it important to investigate if the practice of adding a NSAID (specifically tenoxicam) provides any additional efficacy to a paracetamolcodeine combination on its own.
The optimal dose of tenoxicam for perioperative analgesia is not clear. A single dose of 20 mg i.v. produces blood concentrations of only 3 mg litre 91 compared with more than 10 mg litre 91 at steady state with 20 mg daily by mouth. 28 A loading dose would seem rational, given the long half-life of tenoxicam. 4 The manufacturer advises 40 mg daily for 5 days in the context of postoperative pain relief, 29 but Scaglione and colleagues have demonstrated that single 40-mg loading doses for 2 days, followed by once-daily 20-mg maintenance administration established the requisite steady-state tissue concentration of tenoxicam after the second administration. 30 Therefore, the aim of this study was to investigate the efficacy of tenoxicam 20 and 40 mg when used with up to two tablets of Panadeine (paracetamol 500 mg-codeine 8 mg) every 4 h, for pain after oral surgery.
Patients and methods
This study was undertaken between June 2, 1993 and May 25, 1994 . Approval of the regional Ethics Committee and written informed consent from all patients were obtained. In order to have a statistical power of 80% to show a difference between groups of 25 mm on a 100-mm visual analogue scale (VAS), assuming an SD of 30 mm and nominating P:0.05 as significant, 31 Patients were included if they were undergoing surgical removal of at least both lower wisdom teeth (with or without extraction of one or two upper wisdom teeth), under general anaesthesia in a day-stay facility. Exclusion criteria were: hypersensitivity to aspirin or other NSAID; asthma; history of peptic ulceration, gastrointestinal bleeding or any bleeding disorder; presence of severe renal impairment (creatinine Ն0.2 mg ml 91 ), hepatic, cardiac or haemopoietic disease; pregnancy; presence of any neurological disorder liable to interfere with perception of pain; history of drug addiction; presence of severe local infection; current use of another experimental agent; previous general anaesthetic within 6 months; and use of NSAID, opioids, diuretics or angiotensin converting enzyme inhibitors in the 24 h preceding surgery.
Anaesthesia was induced with a sleep dose of propofol and maintained with halothane and nitrous oxide in oxygen. Patients breathed spontaneously via a nasal airway or a laryngeal mask, with appropriate packing of the oropharynx. All patients received amoxycillin or erythromycin (if allergic to amoxycillin) before and after surgery. No opioids were given. Monitoring was in accordance with the guidelines of the Australian and New Zealand College of Anaesthetists (ANZCA). 32 All extractions were carried out by one of two surgeons who used a standardized technique, except that local anaesthetic blocks with 2% lidocaine (lignocaine) with epinephrine (adrenaline) 1:80 000 were used by one (J. E.) but not the other (P. S.), in accordance with normal practice. They rated the difficulty of the extraction in each case.
Patients were allocated randomly, in blocks of 15 with stratification for surgeon, to receive tenoxicam 40 mg, 20 mg or placebo (groups T40, T20 and PG, respectively). The medication was given i.v. immediately after induction of anaesthesia and orally (as effervescent tablets dissolved in water) with food (at breakfast) on days 1 and 2 (the day of surgery being day 0). The study was double-blind, with no access to the codes, other than by a formalized contingency protocol, until all data had been entered into the computer and verified against a subset re-entered by a second person. No interim analysis was undertaken.
Two tablets of Panadeine (paracetamol 500 mg with codeine 8 mg) were given 45 min before operation to provide basal analgesia. Panadeine tablets were available on an "as required" basis after operation up to a maximum of two tablets 4-hourly. Consumption over days 0-5 was monitored and checked against medication at the end. Nefopam 20 mg i.v. (repeated once if necessary) was also available while in hospital for severe pain.
The primary outcome variable was pain, which was assessed using a 100-mm unmarked visual analogue scale (VAS) with the anchors "no pain" and "severe pain". Patients indicated their "present pain" in hospital 1 h after operation (day 0) and daily (including the day of discharge) at approximately 18:00 (days 0a-5). Each of the latter scores were marked by the patient on a separate VAS included as part of individual pages of a diary. Patients were also asked to assess their pain on a VAS immediately before operation. A daily follow-up telephone call to each patient was made on days 0-6 by the study nurse at approximately 18:00 as a reminder to record their present pain on that day's VAS and to ask about any adverse events which were recorded. At the day 1 telephone call, a categorical rating (as "nil", "mild", "moderate" or "severe", recorded as 0-4) was obtained for pain experienced over the first 24 h after surgery. A similar rating of sleep disruption during the preceding night, attributed by the patient to pain, was obtained at every telephone call from day 1 onwards. Panadeine consumption was also recorded daily. While the patient was in hospital, the study nurse also recorded the following: heart rate, ventilatory frequency and arterial pressure (before and after surgery); sedation rating, nausea rating, vomiting, consumption of antiemetic medication and use of rescue nefopam (after surgery). During the last telephone interview, she asked patients to rate the experience of taking part in the study. Patients were assessed at clinic by the surgeon after 7 days. Haemoglobin and creatinine concentrations were measured during operation and at the routine followup. Any adverse event was allocated a severity rating jointly by two investigators according to a standard protocol developed by Roche Products. The investigators judged the relationship between these events and the study drug as definite, possible or probable, but all events were recorded to ensure that no events were inappropriately suppressed.
The processes involved with data collection were twice subjected to formal audit by a person not associated with the study. Patients received a small payment (NZ$100) to defray the expense associated with attending a laboratory for the second blood sample and to acknowledge the inconvenience of taking part in the study.
Area under the curve (AUC 0-5 ) of the pain VAS (in mm days) for each patient was calculated for days 0-5 starting from 1 h after operation. Panadeine consumption (in tablets) and sleep disturbance scores were summed for days 0-5. Categorical ratings of pain over the first 24 h and VAS at 18:00 on the day of surgery (day 0a) were analysed separately as indicators of early efficacy. None of these variables was normally distributed, even after logarithmic and other transformations were performed, and therefore all efficacy data were analysed using the non-parametric Kruskal-Wallis ANOVA, unless otherwise stated. For each variable, the planned orthogonal contrasts (PG vs the combined tenoxicam groups and T40 vs T20) were calculated when the treatment main effect was significant (specified as PՅ0.05). Repeated measures ANOVA was used to examine differences between groups in changes between preoperative and postoperative values of haemoglobin, creatinine, heart rate, ventilatory frequency and arterial pressure. All P values are reported without correction.
Results
We screened 143 patients. An ampoule of study medication was opened for a recruited patient who did not attend, and therefore 89 patients took part in the study. The reasons for the other exclusions are listed in table 1. There were no other withdrawals and no early code breaks.
Treatment groups were similar in age, ethnic group, concomitant medication and secondary diagnosis, but weight and sex were less evenly distributed (table 2) . Seventy-five patients had no preoperative pain; the remainder were well distributed between the three groups.
Six patients required nefopam in the immediate postoperative period: four in the T40 group and one each in groups T20 and PG (Fisher's exact test; ns). There was no significant difference between groups or surgeons for extraction difficulty or duration of operation. Minor discrepancies in Panadeine consumption, identified by checking returned tablets, were similar between groups. Analysis on the basis of returned tablets gave essentially identical results to those reported below.
Males had higher pain scores than females but this difference was not significant (P:0.4; median scores for AUC 0-5 were 132.4 and 100.9 mm days, respectively).
There was no significant difference between surgeons for any outcome variable, except in the first hour after operation, when pain scores favoured the surgeon who used local anaesthetic (median 10 (interquartile range 2, 37) and 43 (26, 58) for rest pain VAS and 8 (2, 44) and 45 (28, 59 ) for pain on talking VAS, respectively; P:0.01). This was not the case, however, for the categorical assessment of overall pain for the first day (P:0.86) or for pain scores at rest at 18:00 on the day of surgery (P:0.66).
There was a significant difference in pain at rest AUC 0-5 between the three groups: median 167.7 (interquartile range 94.5, 257.5), 89.9 (43.8, 140.7) and 86.9 (41.3, 184.8) mm days for groups PG, T20 and T40, respectively (P:0.04). This was attributable to a significant advantage for the combined tenoxicam groups compared with the placebo group (P:0.016) but there was no significant difference between groups T20 and T40 ( fig. 1) . The significant advantage for the combined tenoxicam groups persisted for days 0-3 (table 3) .
There was a significant difference in: total Panadeine consumption over days 0-5 for the three groups ( fig. 2) (median 28 (interquartile range 13,  33) , 16 (8, 30) and 16 (8, 23) for groups PG, T20 and T40, respectively (P:0.024); rest pain VAS at 18:00 on the day of surgery (P:0.01, table 3); verbal pain rating for the first 24 h after surgery (median 3 (interquartile range 3, 3), 2 (2, 3) and 3 (2, 3) for groups PG, T20 and T40, respectively (P:0.02); and total sleep disturbance scores for days 0-5 (median 9 (interquartile range 8, 12), 7 (6, 9) and 8 (6, 9) for groups PG, T20 and T40, respectively (P:0.01). These were attributable in each case to a highly significant advantage (P:0.01) for the combined tenoxicam groups compared with the placebo group, with no significant difference between groups T20 and T40. There was no significant difference in pain on talking for any measurement, although the trends were generally in the direction of the significant findings. Mean haemoglobin concentration decreased for the three groups combined, from 143 (SD 13) g litre ) was in a patient who received placebo. Systolic arterial pressure, heart rate and ventilatory frequency did not change significantly after operation and there was no significant difference between groups.
Thirty-eight patients reported a total of 63 adverse events, but no patient had to discontinue treatment because of an adverse effect, no adverse effect persisted beyond 2 days and no significant differences between groups were found (table 4) .
Seventy-eight patients rated the experience of taking part in the study as "very positive" or "positive"; 11 considered it "neutral".
Discussion
Patients who received tenoxicam experienced significantly less pain at rest and less disturbance of sleep over the 5 days from the day of surgery than those who received placebo, even though they used significantly fewer Panadeine tablets.
In the tenoxicam groups, patients were heavier, and there was a greater proportion of males and patients who used nefopam. Heavier patients would be expected to have lower plasma concentrations of paracetamol and tenoxicam, and therefore the imbalance in weight seems unlikely to account for our findings. Our males reported slightly higher pain scores overall than females (ns), but this also unlikely to have confounded our results. It is also unlikely that a single dose of the short-acting analgesic nefopam would have had much impact on data amalgamated over 5 days. Table 4 Adverse events by study group, expressed as number of patients experiencing the event (n) and as a percentage (%) of patients in the group, with 95% confidence intervals. Note that the upper 95% confidence limit for those adverse events not actually seen in any given group is 10%, and therefore there is no significant difference between groups for any of these factors. *The three patients who bled more than expected did so on day 0. One patient in the T40 group was graded severe, the other two mild. A surgical cause was identified in each and none was attributed to the study medication by the surgeon. **The column totals exceed the number of patients and differ from the total number of incidents because some patients reported more than one incident; in particular, most who vomited also reported nausea. For the same reason, it is not possible to report total number of incidents as a percentage with confidence intervals because there is no denominator. ***In no patient was the severity sufficient to warrant discontinuation of the medication We did not attempt to measure tissue swelling 33 because this would have necessitated repeated clinic visits and because our primary interest was pain relief. We were surprised at the lack of an effect on pain while talking. The principle that pain should be measured during activity and at rest is well established, but it is not quite so obvious what the specific activity should be in the case of oral surgery; perhaps eating would be more relevant. A loading dose of tenoxicam is pharmacokinetically rational, 28 30 and therefore we were surprised to find no significant difference between the 20-mg and 40-mg doses. Heinaro, Klami and Vaaja also found essentially similar efficacy between 20 mg and 40 mg, in a single oral dose. 17 A dose of 20 mg daily for 3 days, in combination with freely available Panadeine, seems to be effective for pain after oral surgery and the number of patients needed to show a small additional benefit, if present, would be large.
This study was not designed to examine the question of pre-emptive analgesia. 34 However, one surgeon routinely used local anaesthetic before extraction of teeth, and the other did not. As neither was comfortable with modifying his standard practice we resorted to stratification by surgeon to take account of this factor, thus incidentally permitting a comparison of the two approaches, albeit on neither a blinded nor a randomized basis. Pain scores were significantly lower in the local anaesthetic group at 1 h after surgery, when the local anaesthetic was presumably still effective. However, there was no difference in any other outcome variable examined. Even by 18:00 on the day of surgery, no benefit was discernible, and the retrospective assessment of pain for the whole of the first day was not different between groups.
It seems reasonable to conclude that our patients tolerated tenoxicam well in either regimen. No patient discontinued the medication before completing the study, and no patient complained of gastric discomfort; thus the upper 95% confidence limit of the incidence of this symptom with our regimen of tenoxicam was no higher than 5%. 35 The lack of a difference between groups in the incidence of nausea and vomiting is consistent with previous studies of perioperative NSAID. 1 13 Safety is a different issue from the tolerability of a given regimen. A large prospective study is needed to quantify accurately the incidence of serious adverse events associated with perioperative NSAID and even then the question of risk vs benefit would probably remain a matter of opinion. The fact that there was no difference between groups for any adverse effect is consistent with many previous studies of perioperative NSAID, 1 but analgesic studies (including ours) are typically too small to allow comment on uncommon side effects, or on modest differences in the incidences of relatively common side effects. It should also be noted that our patients were healthy young adults, carefully selected to have no contraindications to NSAID, undergoing minor ambulatory surgery and taking the NSAID with food, for only 3 consecutive days. The value of a medication is reduced if large numbers of patients are unable to take it because of contraindications. It is of interest, therefore, that in the group of patients screened for this study, only five of 143 were excluded for this reason. Nevertheless, there have been numerous case reports of various side effects with NSAID and it is necessary to use them with care, particularly in the perioperative period. 1 The analgesic efficacy of perioperative tenoxicam has been studied previously, in major and minor surgery. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] We wanted to know not if tenoxicam was superior to placebo but if analgesia achieved by combining tenoxicam with paracetamol and codeine was superior to that of a paracetamol-codeine regimen alone. It is not clear from our data if Panadeine and tenoxicam had any synergistic effect, but it is clear that the addition of the NSAID provided better analgesia than could conveniently be achieved with a regimen of a paracetamol-codeine combination selfadministered as needed, to a limit of two tablets 4-hourly, with no NSAID and that this was associated with less disturbance of sleep. We were surprised at how long tenoxicam continued to provide analgesia (table 3) or, from a different perspective, how long significant pain persisted after oral surgery.
It is possible that strict adherence to a regular regimen of paracetamol (or Panadeine) might have provided analgesia equal to or better than that achieved with the combination of Panadeine and tenoxicam. Anderson, Kanagasundarum and Woollard have recently shown a relationship between plasma paracetamol concentrations and analgesic efficacy. 36 For single-dose applications this should facilitate much better analgesia with paracetamol than has often been achieved in the past, but the pharmacokinetics of paracetamol do not readily lend themselves to maintaining plasma concentrations continuously above the required threshold for several days; increasing the dose beyond a reasonable limit may increase the risk of hepatotoxicity. 37 Further, our protocol reflects the clinical reality that most patients take simple analgesics on a self-titrated basis whatever the prescription. There is probably little difference between Panadeine (which contains only 8 mg of codeine per 500 mg of paracetamol) and pure paracetamol 38 ; using more codeine on a repeated basis would probably increase the incidence of codeine-related side effects, and any analgesic gains would probably be slight. 38 This study involved some inconvenience to the participants, and we were gratified to record that most patients felt positive about partaking in the study.
In summary, our data showed that tenoxicam provided a simple and well tolerated method of improving analgesia achievable with patient-titrated Panadeine alone, for several days after oral surgery. It was not the purpose of this study to compare the efficacy of tenoxicam with other NSAID which have been studied in a similar setting, 39 and our findings may well be true of most perioperative NSAID and for many different types of surgery; they probably also apply equally to paracetamol without codeine. It would be useful to confirm the value of other such combinations and to identify optimal regimens for particular perioperative models. Most importantly, there is a need for information from much larger studies on the incidence of serious side effects with perioperative NSAID. 1 ial assistance. We also thank Roche Products (New Zealand) Ltd for financial support.
